Escitalopram: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
{{TOC|right}} | {{TOC|right}} | ||
In [[psychiatry]], '''escitalopram''' is a [[second-generation antidepressant]] for treating [[major depressive disorder]]. Escitalopram is the S-enantiomer of racemic [[citalopram]].<ref name="pmid19370639">{{cite journal| author=Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H et al.| title=Escitalopram versus other antidepressive agents for depression. | journal=Cochrane Database Syst Rev | year= 2009 | volume= | issue= 2 | pages= CD006532 | pmid=19370639 | In [[psychiatry]], '''escitalopram''' is a [[second-generation antidepressant]] for treating [[major depressive disorder]]. It is also effective in reducing [[ethanol]] uptake in [[alcoholism|alcoholics]] and is used in depressed patients who also suffer from [[tardive dyskinesia]] in preference to [[tricyclic antidepressant]]s, which aggravate this condition. <ref> {{MeSH}}</ref> | ||
Escitalopram is the S-enantiomer of racemic [[citalopram]].<ref name="pmid19370639">{{cite journal| author=Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H et al.| title=Escitalopram versus other antidepressive agents for depression. | journal=Cochrane Database Syst Rev | year= 2009 | volume= | issue= 2 | pages= CD006532 | pmid=19370639 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19370639 | doi=10.1002/14651858.CD006532.pub2 }} </ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19370639 | doi=10.1002/14651858.CD006532.pub2 }} </ref> | ||
==History== | ==History== | ||
Revision as of 10:11, 17 April 2010
In psychiatry, escitalopram is a second-generation antidepressant for treating major depressive disorder. It is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition. [1]
Escitalopram is the S-enantiomer of racemic citalopram.[2]
History
Lexapro brand of escitalopram was approved by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 2002.[3]
Efficacy
According to a systematic review by the Cochrane Collaboration:[2]
- "Some statistically significant differences favouring escitalopram over other antidepressive agents for the acute phase treatment of major depression were found, in terms of efficacy (citalopram and fluoxetine) and acceptability (duloxetine). There is insufficient evidence to detect a difference between escitalopram and other antidepressants in early response to treatment (after two weeks of treatment). Cost-effectiveness information is also needed in the field of antidepressant trials. Furthermore, as with most standard systematic reviews, the findings rely on evidence from direct comparisons. The potential for overestimation of treatment effect due to sponsorship bias should also be borne in mind."
External links
The most up-to-date information about Escitalopram and other drugs can be found at the following sites.
- Escitalopram - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Escitalopram - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Escitalopram - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Escitalopram (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H et al. (2009). "Escitalopram versus other antidepressive agents for depression.". Cochrane Database Syst Rev (2): CD006532. DOI:10.1002/14651858.CD006532.pub2. PMID 19370639. Research Blogging.
- ↑ Drugs@FDA.